Does NIRAPARIB Cause Neoplasm recurrence? 65 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 65 reports of Neoplasm recurrence have been filed in association with NIRAPARIB (ZEJULA). This represents 0.3% of all adverse event reports for NIRAPARIB.
65
Reports of Neoplasm recurrence with NIRAPARIB
0.3%
of all NIRAPARIB reports
3
Deaths
13
Hospitalizations
How Dangerous Is Neoplasm recurrence From NIRAPARIB?
Of the 65 reports, 3 (4.6%) resulted in death, 13 (20.0%) required hospitalization, and 8 (12.3%) were considered life-threatening.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIRAPARIB. However, 65 reports have been filed with the FAERS database.
What Other Side Effects Does NIRAPARIB Cause?
Nausea (5,794)
Fatigue (5,240)
Constipation (4,128)
Platelet count decreased (4,102)
Insomnia (2,861)
Blood pressure increased (2,464)
Headache (2,383)
Off label use (2,213)
Vomiting (2,029)
Carbohydrate antigen 125 increased (1,868)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which NIRAPARIB Alternatives Have Lower Neoplasm recurrence Risk?
NIRAPARIB vs NIRMATRELVIR\RITONAVIR
NIRAPARIB vs NIROGACESTAT
NIRAPARIB vs NIROGACESTAT HYDROBROMIDE
NIRAPARIB vs NIRSEVIMAB
NIRAPARIB vs NIRSEVIMAB-ALIP